Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 4—April 2013
CME ACTIVITY - Research

Serotype IV and Invasive Group B Streptococcus Disease in Neonates, Minnesota, USA, 2000–20101

Patricia FerrieriComments to Author , Ruth Lynfield, Roberta Creti, and Aurea E. Flores
Author affiliations: University of Minnesota Medical School, Minneapolis, Minnesota, USA (P. Ferrieri, A.E. Flores); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield); Istituto Superiore di Sanità, Rome, Italy (R. Creti)

Main Article

Table 4

Clindamycin susceptibility profiles of GBS isolates from 45 infants with invasive GBS disease, Minnesota, USA, 2010*

Antimicrobial susceptibility profile†
CPS serotype
Total
Clindamycin Erythromycin D-test Ia Ib II III IV V
S S Not done 7 1 0 13 1 2 24
S R Negative 4 0 0 3 0 0 7
S→R R Positive 1 1 0 2 0 0 4
R
R
Not done

0
2
1
0
4
3
10
Total no. 12 4 1 18 5 5 45
No. (%) resistant 1 (8.3) 3 (75.0) 1 2 (11.1) 4 (80.0) 3 (60.0) 14 (31.1)

*GBS, group B Streptococcus; CPS, capsular polysaccharide serotype.
†S, susceptible, MIC <0.25 μg/mL; R, resistant, MIC >1 μg/mL; S→R, inducible resistance to clindamycin indicated by positive D-zone test (double-disk diffusion test).

Main Article

1This work was presented in part at the XVIII Lancefield International Symposium on Streptococci and Streptococcal Diseases, September 4–8, 2011, Palermo, Italy.

Page created: March 14, 2013
Page updated: March 14, 2013
Page reviewed: March 14, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external